Being a European Commission Horizon 2020 beneficiary has a distinct positive impact on our development. The 2.2 M€ grant enables us to proceed faster towards a new drug against chronic inflammatory diseases. To further increase the momentum we are now raising additional funding by a share issue. Interested investors get a chance to join the [...]
A range of CMO partners have been evaluated for cell line development and production of Lipum’s antibody. Next weeks our CEO and CMC Project Manager will travel to both Europe and the US visiting contract manufacturers before selecting this critical collaboration partner. To be continued ...
An article from Biostock In the northern of Sweden, Umeå, the privately owned company Lipum wants to draw the game plan for the treatment of chronic inflammatory diseases. The main assets are a new drug candidate and promising preclinical result for a unique target molecule. BioStock has met CEO Einar Pontén and discussed the past year [...]
An opportunity for investors on Thursday the 7th of February 2019. An efficient full day of exclusive one-to-one partnering at the Biotech Umeå Investment Day 2019. Book your meeting with Lipum at Grand Hôtel in Stockholm. In addition, you can meet with up to 14 different life science companies that are in early development or [...]
Lipum offer a new route for treatment of chronic inflammatory diseases. Meet with our CEO Einar Pontén and our CMC Project Manager Mats Reslow at BIO-Europe 2018 in Copenhagen, Nov 5-7. We will tell you more on our novel target Bile Salt-Stimulated Lipase (BSSL) and our ongoing development of a therapeutic antibody for treatment of these [...]
Lipum's unique approach for treatment of chronic inflammatory diseases receives 2.2 M€ support from EU Horizon 2020, the EU framework program for research and development, will grant 2.2 million euros to Lipum’s ongoing development of a biological pharmaceutical for treatment of chronic inflammatory diseases. Lipum has identified the novel target molecule Bile Salt-Stimulated Lipase (BSSL). [...]
Lipum and some listed nordic life science companies will make company presentations in Stockholm at Nyhetsbyrån Direkt on August 29, 2018. The event is organised by Biostock and will also be broadcasted with start at 09:00. It is free of charge, sign up here.
An international panel of life science investors have selected Lipum as one of 12 companies for the final of the live pitch competition at the Nordic Life Science Days 2018. Learn more about Lipum and other successful companies. We will also attend the partnering activities during the NLSDays in Stockholm, Sept 10-12. Please contact us [...]
Our project "Validation of a biological candidate drug" has been granted support from SWElife "Projects for better health" program. The competition was fierce so the green tie was used during the interview and Lipum was then one of 22 projects granted. In total 123 applications were submitted, read more (Swedish). - This is a quality stamp [...]
Learn more about our novel target for treatment of chronic inflammatory diseases at Biotrinity - A Leading Biopartnering and Investment Conference in London, April 23-25, 2018 We will tell you more about Bile Salt-Stimulated Lipase (BSSL) and our ongoing development of a therapeutic antibody. Lipum has collected original research data proving the efficacy of the [...]